如何治疗接受分化治疗的急性髓系白血病
该综述讨论急性髓系白血病(AML)分化治疗的作用机制与分化综合征(DS)的识别处理。全反式维甲酸和三氧化二砷是急性早幼粒细胞白血病经典分化剂,异柠檬酸脱氢酶1和2抑制剂、FMS样酪氨酸激酶3抑制剂及menin抑制剂也通过分化起效。DS主要表现为呼吸困难、肺部浸润、胸膜和心包积液、不明原因发热、低血压、水肿和肾功能不全;新诊断APL的DS易识别,多次复发AML的DS诊断更困难。及时考虑DS、迅速启用全身性糖皮质激素,并在合并高白细胞血症时早期减细胞,对最佳管理至关重要。
要点
- 全反式维甲酸和三氧化二砷是急性早幼粒细胞白血病的经典分化剂。
- 异柠檬酸脱氢酶1和2抑制剂、FMS样酪氨酸激酶3抑制剂及menin抑制剂也通过分化发挥作用。
- 分化综合征以呼吸困难、肺部浸润、浆膜腔积液、发热、低血压、水肿和肾功能不全为特征。
核心结论
- 及时考虑分化综合征、迅速启用全身性糖皮质激素,并在合并高白细胞血症时早期减细胞,对最佳管理至关重要。
研究设计与样本
- 本文为综述,讨论急性髓系白血病分化治疗及分化综合征的识别与处理。
主要发现
- 全反式维甲酸和三氧化二砷是治疗急性早幼粒细胞白血病的经典分化剂。
- 异柠檬酸脱氢酶1和2抑制剂、FMS样酪氨酸激酶3抑制剂及menin抑制剂是较新的通过分化起效的疗法。
- 分化综合征主要表现为呼吸困难、肺部浸润、胸膜和心包积液、不明原因发热、低血压、水肿和肾功能不全。
- 新诊断急性早幼粒细胞白血病患者的分化综合征通常容易识别,多次复发急性髓系白血病患者的分化综合征诊断更具挑战性。
临床怎么用
- 及时考虑分化综合征、迅速启用全身性糖皮质激素,并在合并高白细胞血症时早期减细胞,对最佳管理至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An increasing number of acute myeloid leukemia (AML) therapeutics have been developed, not as cytotoxic therapies but rather as targeted agents able to restore the aberrant and leukemogenic "block" in normal differentiation. All-trans retinoic acid and arsenic trioxide are classic examples of differentiating agents for treatment of acute promyelocytic leukemia (APL); newer therapies functioning through differentiation include isocitrate dehydrogenase 1 and 2 inhibitors, FMS-like tyrosine kinase 3 inhibitors, and menin inhibitors. The terminal differentiation of leukemic blasts via differentiating-agent therapy can lead to a constellation of signs and symptoms, originally referred to as "retinoic acid syndrome" and now termed "differentiation syndrome" (DS), characterized predominantly by systemic inflammatory response system-like features of dyspnea, pulmonary infiltrates, pleural and pericardial effusions, unexplained fevers, hypotension, edema, and renal insufficiency. DS in patients with newly diagnosed APL is generally straightforward to identify; however, DS in patients with multiply relapsed AML can be more challenging to diagnose, due to nonspecific signs and symptoms that can be mistakenly attributed to infectious etiologies or the underlying refractory leukemia itself. Prompt consideration of DS, rapid initiation of systemic corticosteroids, and early cytoreduction in the setting of concomitant hyperleukocytosis are essential for optimal management.
引用
- Issa GC, Stein EM, DiNardo CD, et al. How I treat acute myeloid leukemia with differentiation therapy. Blood. 2025. PMID: 38976876. doi:10.1182/blood.2024024008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。